CSF1R and melanoma: As additional murine melanoma BRAFV600E cell lines and corresponding mouse models of melanoma are developed, the effects of PLX4032 combined with other therapeutic agents such as CSF-1R inhibitors may lead to stronger synergistic antitumor responses.